Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Ether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL244987 | 1.00 | — | — | |
| Ether SCHEMBL11292739 | 0.90 | — | — | |
| Ether SCHEMBL12501209 | 0.90 | — | — | |
| Ether SCHEMBL1375446 | 0.90 | — | — | |
| Ether SCHEMBL2812813 | 0.90 | — | — | |
| Ether SCHEMBL4855472 | 0.90 | — | — | |
| Ether SCHEMBL11335832 | 0.90 | — | — | |
| Ether SCHEMBL21406 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TSHRTHRB | |
| Ether SCHEMBL8160191 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TSHRTHRB | |
| Ether SCHEMBL9248046 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556378-B1 | ACYL DERIVATIVES OF 5-(2-(4-(1,2 BENZISOTHIAZOLE-3-YL)-1-PIPERAZINYL)ETHYL)-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HAVING NEUROLEPTIC ACTIVITY | PFIZER PROD INC (US) | 2008-01-09 | — | — | EP | claimed |
| CN-100340557-C | Acyl derivatives of ziprasidone having neuroleptic activity | PFIZER PROD INC (US) | 2007-10-03 | — | — | CN | claimed |
| US-7019009-B2 | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity | PFIZER INC. (US) | 2006-03-28 | — | — | US | claimed |
| CN-1705663-A | Acyl derivatives of 5- (2- (4- (1, 2-benzisothiazol-3-yl) -1-pyrazinyl) ethyl) -6-chloro-1, 3-dihydro-2H-indol-2-one having neuroleptic activity | PFIZER PROD INC (US) | 2005-12-07 | — | — | CN | claimed |
| EP-1556378-A1 | ACYL DERIVATIVES OF 5-(2-(4-(1,2 BENZISOTHIAZOLE-3-YL)-1-PIPERAZINYL)ETHYL)-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HAVING NEUROLEPTIC ACTIVITY | Pfizer Products Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| US-20040138232-A1 | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity | PFIZER INC | 2004-07-15 | — | — | US | claimed |
| WO-2004037819-A1 | ACYL DERIVATIVES OF 5-(2-(4-(1,2 BENZISOTHIAZOLE-3-YL)-1-PIPERAZINYL)ETHYL)-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HAVING NEUROLEPTIC ACTIVITY | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138232-A1 | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity | AANAT, TPH1, TPH2 | ALDH1A1 191/4885TSHR 1805/4885THRB 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.